BMS-212122

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524453

CAS#: 194213-64-4

Description: BMS-212122 is a potent microsomal triglyceride transfer protein inhibitor (MTP inhibitor). MS-212122 is significantly more potent than BMS-201038 in reducing plasma lipids (cholesterol, VLDL/LDL, TG) in both hamsters and cynomolgus monkeys. Treatment with BMS-212122 led to rapid reduction in plasma lipid levels, which were accompanied by a significant decrease in lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques compared to baseline and chow diet control groups. BMS-212122-treated mice had increased collagen content, a marker associated with increased stability in human plaques.


Chemical Structure

img
BMS-212122
CAS# 194213-64-4

Theoretical Analysis

MedKoo Cat#: 524453
Name: BMS-212122
CAS#: 194213-64-4
Chemical Formula: C43H36F6N4O2
Exact Mass: 754.27
Molecular Weight: 754.760
Elemental Analysis: C, 68.43; H, 4.81; F, 15.10; N, 7.42; O, 4.24

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: BMS-212122; BMS212122; BMS 212122; UNII-0Z473OO6GB.

IUPAC/Chemical Name: 9-(4-(2,5-dimethyl-4-(4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamido)-1H-benzo[d]imidazol-1-yl)butyl)-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide

InChi Key: PCOWNQCLFYEXLR-UHFFFAOYSA-N

InChi Code: InChI=1S/C43H36F6N4O2/c1-26-17-22-36-38(37(26)52-39(54)33-14-4-3-11-30(33)28-18-20-29(21-19-28)43(47,48)49)51-27(2)53(36)24-10-9-23-41(40(55)50-25-42(44,45)46)34-15-7-5-12-31(34)32-13-6-8-16-35(32)41/h3-8,11-22H,9-10,23-25H2,1-2H3,(H,50,55)(H,52,54)

SMILES Code: O=C(C1(CCCCN2C3=CC=C(C)C(NC(C4=CC=CC=C4C5=CC=C(C(F)(F)F)C=C5)=O)=C3N=C2C)C6=C(C7=C1C=CC=C7)C=CC=C6)NCC(F)(F)F

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 754.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hewing B, Parathath S, Mai CK, Fiel MI, Guo L, Fisher EA. Rapid regression of
atherosclerosis with MTP inhibitor treatment. Atherosclerosis. 2013
Mar;227(1):125-9. doi: 10.1016/j.atherosclerosis.2012.12.026. PubMed PMID:
23332773; PubMed Central PMCID: PMC4047651.


2: Robl JA, Sulsky R, Sun CQ, Simpkins LM, Wang T, Dickson JK Jr, Chen Y, Magnin
DR, Taunk P, Slusarchyk WA, Biller SA, Lan SJ, Connolly F, Kunselman LK, Sabrah
T, Jamil H, Gordon D, Harrity TW, Wetterau JR. A novel series of highly potent
benzimidazole-based microsomal triglyceride transfer protein inhibitors. J Med
Chem. 2001 Mar 15;44(6):851-6. PubMed PMID: 11300866.


3: Dikkers A, Annema W, de Boer JF, Iqbal J, Hussain MM, Tietge UJ. Differential
impact of hepatic deficiency and total body inhibition of MTP on cholesterol
metabolism and RCT in mice. J Lipid Res. 2014 May;55(5):816-25. doi:
10.1194/jlr.M042986. PubMed PMID: 24511105; PubMed Central PMCID: PMC3995460.